These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38615313)

  • 1. The temporal association between adverse drug reactions and antirheumatic drugs utilisation in Western Australia: a retrospective study from real-world data (1995-2015).
    Almutairi KB; Inderjeeth CA; Preen DB; Keen HI; Nossent JC
    Rheumatol Int; 2024 Jun; 44(6):1089-1099. PubMed ID: 38615313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten.
    Yukselen Z; Raju AKV; Kumar PA; Ujjawal A; Dasari M; Parajuli S; Nakhla M; Bansal K; Ganatra S; Dani SS
    Am J Cardiovasc Drugs; 2024 Nov; 24(6):791-799. PubMed ID: 39164512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
    Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
    Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the Safety Profile of Fast-Track COVID-19 Drugs Using the FDA Adverse Event Reporting System Database: A Comparative Observational Study.
    Kim HJ; Yoon JH; Lee KH
    Pharmacoepidemiol Drug Saf; 2024 Nov; 33(11):e70043. PubMed ID: 39533148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients.
    Giraud EL; Jessurun NT; van Hunsel FPAM; van Puijenbroek EP; van Tubergen A; Ten Klooster PM; Vonkeman HE
    Expert Opin Drug Saf; 2020 Dec; 19(12):1617-1624. PubMed ID: 32990050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia).
    De Las Cuevas C; Sanz EJ; de Leon J
    Schizophr Res; 2024 Jun; 268():165-174. PubMed ID: 37301669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
    Svendsen K; Wood M; Olsson E; Nordeng H
    Eur J Clin Pharmacol; 2018 May; 74(5):627-636. PubMed ID: 29290074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentially inappropriate medications and adverse drug reactions in the elderly: a study in a PharmacoVigilance database.
    Montastruc F; Duguet C; Rousseau V; Bagheri H; Montastruc JL
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1123-7. PubMed ID: 24925091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
    Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009.
    Aldea A; García Sánchez-Colomer M; Fernández Quintana E; García Sáiz M
    Eur J Clin Pharmacol; 2012 Sep; 68(9):1329-38. PubMed ID: 22415248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
    Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
    Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical adverse drug reactions: descriptive analysis of French reports.
    Hakimi Y; Petitpain N; Pinzani V; Montastruc JL; Bagheri H
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1169-1174. PubMed ID: 32418024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil.
    Lobo MG; Pinheiro SM; Castro JG; Momenté VG; Pranchevicius MC
    BMC Pharmacol Toxicol; 2013 Jan; 14():5. PubMed ID: 23298396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.
    Cliff-Eribo KO; Sammons H; Choonara I
    Expert Opin Drug Saf; 2016 Oct; 15(10):1321-8. PubMed ID: 27501085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.